Pharma Aids (DHA:PHARMAID) Cyclically Adjusted Revenue per Share: BDT116.83 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:PHARMAID Pharma Aids Ltd DHA:PHARMAID
73 GF Score
Price BDT607.90
GF Value BDT762.54
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Pharma Aids Cyclically Adjusted Revenue per Share?

Pharma Aids DHA:PHARMAID -0.51% 73 Cyclically Adjusted Revenue per Share is BDT116.83 as of Mar. 2026. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT762.54 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharma Aids's adjusted revenue per share for the three months ended in Mar. 2026 was BDT39.503. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is BDT116.83 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pharma Aids's average Cyclically Adjusted Revenue Growth Rate was 12.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pharma Aids was 10.60% per year. The lowest was 10.60% per year. And the median was 10.60% per year.

As of today (2026-08-06), Pharma Aids's current stock price is BDT607.90. Pharma Aids's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was BDT116.83. Pharma Aids's Cyclically Adjusted PS Ratio of today is 5.20.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Aids was 11.84. The lowest was 4.25. And the median was 6.98.


Pharma Aids  (DHA:PHARMAID) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pharma Aids's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=607.90/116.83
=5.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharma Aids was 11.84. The lowest was 4.25. And the median was 6.98.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharma Aids Cyclically Adjusted Revenue per Share Related Terms


Pharma Aids Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pharma Aids's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Aids Cyclically Adjusted Revenue per Share Chart

Pharma Aids Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 78.82 85.43 96.27 106.67

Pharma Aids Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.53 106.67 109.86 112.33 116.83

DHA:PHARMAID vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Pharma Aids's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Aids Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Aids's Cyclically Adjusted PS Ratio falls into.


DHA:PHARMAID
73GF Score
Pharma Aids Ltd DHA:PHARMAID
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Aids Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharma Aids's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=39.503/330.2130*330.2130
=39.503

Current CPI (Mar. 2026) = 330.2130.

Pharma Aids Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 13.946 241.018 19.107
201609 12.859 241.428 17.588
201612 15.010 241.432 20.530
201703 14.613 243.801 19.792
201706 15.286 244.955 20.606
201709 17.060 246.819 22.824
201712 21.148 246.524 28.327
201803 19.149 249.554 25.338
201806 17.977 251.989 23.558
201809 21.144 252.439 27.658
201812 20.641 251.233 27.130
201903 20.971 254.202 27.242
201906 17.049 256.143 21.979
201909 23.035 256.759 29.625
201912 23.831 256.974 30.623
202003 19.125 258.115 24.467
202006 20.409 257.797 26.142
202009 20.693 260.280 26.253
202012 21.647 260.474 27.443
202103 24.339 264.877 30.343
202106 23.158 271.696 28.146
202109 27.479 274.310 33.079
202112 25.999 278.802 30.793
202203 27.378 287.504 31.445
202206 22.685 296.311 25.280
202209 23.422 296.808 26.058
202212 23.766 296.797 26.442
202303 26.844 301.836 29.368
202306 24.844 305.109 26.888
202309 30.080 307.789 32.271
202312 38.724 306.746 41.687
202403 37.415 312.332 39.557
202406 28.770 314.175 30.239
202409 33.250 315.301 34.823
202412 38.871 315.605 40.670
202503 32.704 319.799 33.769
202506 35.588 322.561 36.432
202509 38.185 324.800 38.821
202512 45.602 324.054 46.469
202603 39.503 330.213 39.503

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of BDT116.83 mean?
Pharma Aids (DHA:PHARMAID) has a Cyclically Adjusted Revenue per Share of BDT116.83 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharma Aids and its competitors.
Is Pharma Aids' Cyclically Adjusted Revenue per Share too high?
Pharma Aids' current Cyclically Adjusted Revenue per Share is BDT116.83. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Pharma Aids' Cyclically Adjusted Revenue per Share of BDT116.83 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharma Aids and its competitors. Pharma Aids's current Cyclically Adjusted Revenue per Share is BDT116.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT762.54, compared to a current price of BDT607.90 — trading 20.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is BDT116.83. Pharma Aids' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current Cyclically Adjusted Revenue per Share is BDT116.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued. The current stock price of BDT607.90 is trading 20.3% below its estimated GF Value™ of BDT762.54. GuruFocus considers Pharma Aids to be Modestly Undervalued.

Key valuation signals for DHA:PHARMAID:

  • Cyclically Adjusted Revenue per Share: BDT116.83
  • GF Value™: BDT762.54 vs. price of BDT607.90 (20.3% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma Aids Business Description

Address 345 Segun Bagicha, 1st Floor, Ramna, Dhaka, BGD, 1000
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score

Get the complete analysis for DHA:PHARMAID

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT607.90
Price
BDT762.54
GF Value